GSK H1 FY26 profit attributable to shareholders rises to $2.91 billion; turnover increases to $21.49 billion - GSK News | RalliesGSK H1 FY26 profit attributable to shareholders rises to $2.91 billion; turnover increases to $21.49 billion
G
GSK• GSK reports H1 FY26 results
- GSK posted H1 2026 profit after taxation of $3.21 billion, with earnings per share of 72.4c.
- Turnover totaled $21.49 billion, while operating profit came in at $3.72 billion.
- Vaccines turnover reached $5.94 billion, led by Shingrix at $2.57 billion.
- Specialty Medicines turnover was $9.39 billion, with HIV contributing $5.23 billion.
- General Medicines turnover totaled $6.16 billion, including Respiratory at $4.39 billion.
